ESPE Abstracts

Background: Islet autoantibodies such as Glutamic Acid Decarboxylase (GAD), Islet antigen-2 (IA-2), Zinc Transporter 8 (ZnT8), and Insulin autoantibody (IAA) are known to be detected at higher frequencies in pediatric patients clinically diagnosed with type 2 diabetes than in adults. Therefore, it is crucial to evaluate them for accurate diagnosis, prognosis, and treatment direction. However, guidelines for when to re-evaluate patients with negative islet auto...

Introduction: LADY (latent autoimmune diabetes in youth) have been proposed in younger type 2 DM with presence of beta cell autoantibodies like LADA in adult. LADA patients showed greater complication risk in the later course of disease compared with type 2 DM. When we see the LADY and the LADA in an age-related continuous spectrum, LADY will have more adverse results than type 2 DM. And a large number of LADY is expected as diabetes related autoimmunity in yo...

Recently there has been studies which reported that SGA could be a risk factor for the development of delayed TSH elevation (dTSH) in preterm infant. To our knowledge, very few studies have addressed development of dTSH in SGA infants whose gestational age > 34. We included 76 SGA infants and 83 controls matched on sex and birth weight who showed normal results on the initial thyroid function screening test. On the following test for thyroid function, dTSH prevalence was ...

Background: Triptorelin, a gonadotropin-releasing hormone (GnRH) agonist, is available as 1-, 3-, and 6-month formulation for treatment of central precocious puberty (CPP). The triptorelin 22.5mg as 6-month formulation, which has recently been approved for use in CPP and offers greater convenience to children by reducing the injection frequency, but related research is very limited. The aim of this study was to study on the impact of 6 month formulation on pre...

Introduction: Diabetic retinopathy is a leading microvascular complication and preventable cause of vision loss. NHS diabetes eye screening program (DESP) assesses for early signs, with population prevalence between 3.5% and 24.2%. Understanding the factors involved is important to reduce morbidity.Aims and objectives: Establish clinical characteristics and modifiable risk factors for patients with retinopathy identified...

Introduction: Transition of young adults with diabetes has received much attention in recent years. Despite concerns regarding deterioration in glycaemic control and lack of engagement in services following transfer of care from paediatric to adult services, very few studies have looked at the effect of transfer on glycaemic control and clinic attendance as the primary outcome.Objectives: To establish the glycaemic control and rate of microvascular compl...

Introduction: An important part of diabetes management is maintaining high standards of in-patient care. A previous audit in the South of England demonstrated difficulties consistently achieving standards identified as good practice.Objectives: To identify variations in in-patient care provided to children with type 1 diabetes across the Yorkshire and Humber region.Methods: The audit was conducted against in-patient care standards ...

Background: Metformin is the only oral antihyperglycaemic agent (AHA) approved for use in youths with type 2 diabetes mellitus (T2DM). It may also be used to treat other conditions such as hyperinsulinaemia, pre-diabetes, and polycystic ovarian syndrome (PCOS). Therefore, an assessment of the prevalence of T2DM in the paediatric population based on the utilisations for metformin may overestimate the burden of the disease. However, metformin utilisation patterns in youths remai...

Background: Since metformin (MET), approved for treatment of type 2 diabetes (T2D), is the most commonly used oral anti-hyperglycaemic agent in youths MET prescriptions (Rx) could be used as a proxy for T2D burden in these populations. However, the extent of off-label use of MET in paediatrics is not well studied.Objective and hypotheses: Estimate the annual prevalence of ≥1 MET Rx among youths and calculate proportions with concomitant diagnoses o...

Background: Congenital hypothyroidism is the most common neonatal metabolic disorder and detected at a rate of 1 in 3000 to 4000 live births. Compared to congenital hypothyroidism caused by defects in thyroid development leading to thyroid dysgenesis, thyroid dyshormonogenesis has tendency to be detected at older age and its clinical manifestations are individually different. Thus, to evaluate exact causes and predict clinical course for congenital thyroid dys...